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Macrocyclic lactones (ML) are important anthelmintics used in animals and humans against parasite
nematodes, but their therapeutic success is compromised by the spread of ML resistance. Some ABC
transporters, such as P-glycoproteins (Pgps), are selected and overexpressed in ML-resistant nematodes,
supporting a role for some drug efﬂux proteins in ML resistance. However, the role of such proteins in ML
transport remains to be clariﬁed at the molecular level. Recently, Caenorhabditis elegans Pgp-1 (Cel-Pgp-
1) has been crystallized, and its drug-modulated ATPase function characterized in vitro revealed Cel-Pgp-
1 as a multidrug transporter. Using this crystal structure, we have developed an in silico drug docking
model in order to study the binding of ML and other anthelmintic drugs to Cel-Pgp-1. All tested ML
bound with high afﬁnity in a unique site, within the inner chamber of the protein, supporting that ML
may be transported by Cel-Pgp-1. Interestingly, interacting residues delineate a ML speciﬁc ﬁngerprint
involving H-bonds, including T1028. In particular, benzofurane and spiroketal moieties bound to speciﬁc
sub-sites. When compared with the aglycone ML, such as moxidectin and ivermectin aglycone, aver-
mectin anthelmintics have signiﬁcant higher afﬁnity for Cel-Pgp-1, likely due to the sugar substituent(s)
that bind to a speciﬁc area involving H-bonds at Y771. Triclabendazole, closantel and emodepside bound
with good afﬁnities to different sub-sites in the inner chamber, partially overlapping with the ML binding
site, suggesting that they could compete for Cel-Pgp-1-mediated ML transport. In conclusion, this work
provides novel information on the role of nematode Pgps in transporting anthelmintics, and a valuable
tool to predict drug-drug interactions and to rationally design new competitive inhibitors of clinically-
relevant nematode Pgps, to improve anthelmintic therapeutics.
© 2016 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).bamectin; AH, anthelmintic;
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Macrocyclic lactones (ML) are the most important anthelmintic
(AH) drugs used today for the control of parasitic nematodes and
ectoparasites in animals and humans. Since the discovery of iver-
mectin (IVM) in 1980, several structurally-related ML drugs,
belonging to the avermectin or milbemycin families, have been
marketed. They all exert their anthelmintic effect by binding to
glutamate-gated chloride channels expressed in the nervous sys-
tem, causing paralysis of somatic, pharyngeal or excretory cell
muscles that leads to paralysis, starvation, loss of tolerance to host
immunity and death of the nematode (Cully et al., 1994; Forrester
et al., 2003; Moreno et al., 2010). Overall, besides their excep-
tional safety margin and broad-spectrum activity, ML were previ-
ously effective against parasite strains resistant to older dewormingsitology. This is an open access article under the CC BY-NC-ND license (http://
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development of drug resistance in animal parasites (Jabbar et al.,
2006; Kaplan, 2004), and this phenomenon has also emerged in
human parasites (Osei-Atweneboana et al., 2007, 2011). Because
there are few therapeutic alternatives and new drug discovery is a
very long and expensive process, a challenge for sustainable control
of nematode parasites is to retain the efﬁciency of the existing AH
drugs, including ML, by overcoming the process of AH resistance.
This indicates the urgency to decipher the molecular mechanisms
of anthelmintic resistance in nematodes.
Some active membrane transporters from the ATP-binding
cassette (ABC) family are associated with ML resistance, and
possibly resistance against other AH drugs, in parasite nematodes
(Lespine et al., 2012). Many ABC transporters are present in various
kingdoms, including different infectious agents (Koenderink et al.,
2010; Lage, 2003), where they lead to various multidrug resis-
tance phenotypes (Jones and George, 2005). Interestingly, all these
transporters have two nucleotide binding domains (NBDs), which
are highly conserved sequences giving the hallmark for belonging
to the ABC family (Higgins, 1992). These NBDs bind ATP for hy-
drolysis, providing energy for substrate translocation during the
transport cycle. In addition, ABC efﬂux transporters are all similarly
organized in two transmembrane domains (TMDs) of 6 a-helices
each. These TMDs delineate an “inner chamber” within the mem-
brane where substrates can bind. Although TMDs harbor less
conserved sequences when compared with NBDs, they generally
present a fairly conserved conformational folding between sub-
families and species. These typical structural characteristics sup-
port the notion that these proteins share similar transport mech-
anisms among species (Seeger and van Veen, 2009). In mammals,
multidrug ABC transporters such as P-glycoprotein (MDR1/ABCB1/
Pgp) can efﬂux various, structurally unrelated drugs, and Pgp is
responsible for the multidrug resistance (MDR) in mammalian tu-
mor cells (Eckford and Sharom, 2009; Leonard et al., 2003). Pgp is
also physiologically expressed in the tissue barriers and is involved
in intestinal absorption, cerebral distribution and biliary and uri-
nary excretions. Thereby, it contributes in a signiﬁcant manner to
the pharmacokinetics of a broad range of molecules of pharmaco-
logical interest (Schinkel, 1997). Noticeably, amongst many drugs,
IVM and other ML are transported by mammalian Pgp (Lespine
et al., 2007; Roulet et al., 2003; Schinkel et al., 1994), which con-
tributes to modulating their AH efﬁcacy in the host.
The model free-living nematode, Caenorhabditis elegans (Cel)
genome contains 14 homologs of ABCB/Pgps gene products and 10
are found in the parasitic nematode Haemonchus contortus (Hco)
(Laing et al., 2011, 2013). There is little information on their func-
tions, except that the loss of each of the 14 Pgps increases sus-
ceptibility of C. elegans to IVM to various degrees (Ardelli and
Prichard, 2013; Janssen et al., 2013). Also, induction of expression
of some Pgp genes after selection under IVM pressure is associated
with IVM resistance in C. elegans and in several parasitic nema-
todes, which can be partly reversed by using mammalian Pgp in-
hibitors (James and Davey, 2009; Lespine et al., 2012; Menez et al.,
2016). In addition, ML were shown to inhibit parasitic nematode
Pgp-mediated drug transport in heterologous recombinant systems
overexpressing Hco-Pgp-2, Hco-Pgp-9.1, Hco-Pgp-16, Cylicocylus
elongatus (Ceg)-Pgp-9 or Diroﬁlaria immitis (Dim)-Pgp-11 (Godoy
et al., 2015a, 2015b, 2016; Kaschny et al., 2015; Mani et al., 2016).
Nevertheless, all these data give only indirect evidence that ML can
be substrates of nematode Pgps. Considerable progress was made
when Cel-Pgp-1 was puriﬁed, allowing functional characterization.
Indeed, its stimulation of ATPase activity by mammalian Pgp-
substrate drugs provides the most compelling evidence of a
multidrug transport function for a nematode Pgp, but AH drugs
have not been tested on this relevant experimental system.Therefore, direct information about the molecular relationships
between AH drugs and ABC transporters in nematodes is still
crucially lacking.
In this context, the determination of the crystal structure of Cel-
Pgp-1 at a good atomic resolution (3.4 Å, Protein Data Bank PDB
structure 4F4C) realizes a clear breakthrough as it is a unique and
accurate molecular description of a nematode Pgp (Jin et al., 2012).
Plus, it presents an open inward-facing conformation, deﬁning a
large cavity (the “inner chamber”), which is expected to be
competent for substrate uptake as the ﬁrst step of its transport
enzymatic cycle. Thus, it provides a reliable structural basis to un-
dertake in silico investigations of drug binding by molecular dock-
ing approaches. In this work, we studied the capacity of ML and
other AHs of therapeutic interest to interact with Cel-Pgp-1 using in
silico docking techniques. In order to validate and strengthen the
computational modelling approach, we ﬁrst performed docking
calculations with the drugs identiﬁed as substrates of Cel-Pgp-1 on
the basis of their ability to stimulate its ATPase activity, as previ-
ously demonstrated in vitro (Jin et al., 2012). Brieﬂy, using AutoDock
4 scoring function, we found for all 6 ATPase activators, valino-
mycin, vinblastine, actinomycin D, dipyridamole, progesterone and
paclitaxel, a good to very good binding energy (in the range
from 7.0 to 17.0 kcal mol1) for the best docking poses, which
were all located within the inner chamber of the protein (David
et al., work in process). Furthermore, docking calculations for
positively charged rhodamine 123, taken as a negative control since
it did not stimulate Cel-Pgp-1 ATPase activity, gave two poses that
were either clearly outside the inner chamber or presented a very
weak binding energy (3.8 kcal mol1). This good qualitative and
quantitative agreement for the correlation between in vitro enzy-
mological data and in silico calculations provided conﬁdence for
using our modelling strategy to investigate putative interactions
with Cel-Pgp-1 of compounds belonging to several AH classes. For
the ﬁrst time, we determined the parameters of nematode Pgp-AH
interaction, including binding energy and location of the binding
sites in the protein, with a model nematode Pgp. In particular, we
delineated their predictive binding sites by identifying amino acid
residues that interact with different drug substituents of impor-
tance in the speciﬁc binding of each ML. We thus proposed a mo-
lecular view of the binding of several ML, which showed a uniﬁed
handling by the transporter since they all share a common binding
domain in the inner chamber. Using this model, we compared ML
binding with the binding modes of other AH classes on Cel-Pgp-1,
which all presented different binding sites within the inner
chamber. Our ﬁndings thus provide a signiﬁcant breakthrough in
understanding how AHs bind to nematode Pgps, and provide
strong evidence to indicate that ML can be transported by parasite
nematode Pgp-1 homologs.
2. Computational methods
2.1. Structure of Cel-Pgp-1
The Cel-Pgp-1 X-ray structure, determined at a resolution of
3.4 Å (PDB code 4F4C) (Jin et al., 2012), was used in all docking
calculations. The whole chain A was taken into account, with the
exception of two detergent molecules (undecyl 4-O-alpha-D-glu-
copyranosyl-1-thio-beta-D-glucopyranoside, PDB entry name 0SA),
bound in the inner chamber, and that have been removed for grid
maps calculations. The 4F4C structure includes the full glycosylated
Cel-Pgp-1 sequence (1321 amino acids), but N-terminal (M1-R3)
and C-terminal (G1307-K1321) segments are missing in the struc-
ture, as well as a short segment (A52-E54) located in an extended
loop of the ﬁrst TMD domain, and a 49-residues segment (K666-
E715) belonging to the linker region. Interestingly, an additional
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domain, a structural feature that has not been observed in other
Pgp structures released in the PDB.
Orientations of proteins in membranes database (http://opm.
phar.umich.edu/) allowed the determination of the position of the
lipid bilayer relative to Cel-Pgp-1, which deﬁned the grid box po-
sition. The atomic coordinates PDB ﬁle was then converted into a
PDBQT ﬁle by AutoDock Tools 4 (Morris et al., 2009) for docking
calculations. PyMOL (The PyMOL Molecular Graphics System,
Version 1.3, Schr€odinger, LLC) was used as visualization tools for
various tasks (3D alignments, ligands and hotspots location, grid
box positioning for AutoGrid 4) and for structure rendering in
ﬁgures.
2.2. Preparation and conformational analysis of ligands
The molecular structures of ligands were extracted from
Chemspider (CID), Drugbank (DB) or Merck Index (M)
(Suppl. Fig. S1 and S3), depending on the availability of structures.
Each molecular structure was carefully scrutinized for chirality, and
sometimes corrected when inconsistencies were found in the
literature. For abamectin (ABA), the dry compound is a mixture of
B1a (substituent isobutyl on C25) and B1b (substituent isopropyl on
C25) forms. As B1a is largely predominant in natural mixtures, the
docking calculations were performed only with B1a compound.
Several AHs, i.e. levamisole (LEV), closantel (CLO) and monepantel
(MNP) are used in vivo as racemicmixtures for treatment, which led
us to investigate the docking of each enantiomer.
In the semi-ﬂexible mode, the ligand is handled as ﬂexible
around all the rotatable bonds. However, the conformational space
of the ligand can be poorly explored when it contains ring struc-
tures as in avermectins, since AutoDock does not consider single
bonds in non-aromatic cycles as rotatable bonds. To overcome this
limitation, in order to better sample the initial conformational
space accessible to the ligand, we generated for each ring-
containing compound 10 different low energy conformations. For
this, we used Marvin Sketch and the minimization under the
MMFF94 force ﬁeld provided in Marvin Suite (https://www.
chemaxon.com/products/marvin/marvinsketch/). The diversity of
the 10 lowest energy conformers was evaluated by their pairwise
root mean square deviations (RMSD) for atomic positions after
superimposition under PyMOL. For each obtained cluster of close
conformers, a representative one, deﬁned as the center of the group
according to the calculated RMSDs, was selected. One to ﬁve
different conformers were thus selected as starting points for
further docking procedures. In all cases, the selected conformers
presented rather close energies, corresponding to rapidly inter-
converting forms of the molecule, and the docking results were
generally comparable between each conformer. Thus, the most
representative conformer for docking results was chosen for data
presentation.
2.3. Docking calculations
Molecular docking experiments were performed using Auto-
Dock 4 (release 4.2.6) in the semi-ﬂexible mode with the Cel-Pgp-1
4F4C PDB structure kept rigid, and prepared with AutoDock Tools
(Morris et al., 2009). AutoDock, which is the most cited docking
software (Sousa et al., 2006, 2013), has a free-energy scoring
function based on AMBER force ﬁeld and a large set of diverse
protein-ligand complexes with known inhibition constants. Few
residues of the protein could have been declared as ﬂexible in the
PDBQT ﬁle, but the program restrains the total number of torsional
degrees of freedom to 32, shared between the ligand and the re-
ceptor. This is a drawback in the case of the Cel-Pgp-1 structure,since the inner chamber is large, and in the absence of consistent
indications about the exact location of the binding sites of the
various drugs, different cavities have to be taken into account in the
calculation. Thus, we privileged an approach based on better
coverage of ligand ﬂexibility and a grid box extended to the whole
membrane part of the receptor protein. Indeed, for all ligands
tested, the docking box, in which grid maps were computed using
programAutoGrid 4, encompassed all the TM helices and thewhole
internal cavity, including lateral access channels and protein sur-
face, to allow a large sampling of potential poses. The grid built by
AutoGrid included 100, 124, and 126 points in x, y, and z directions,
with a grid spacing of 0.375 Å to allow a good compromise between
resolution of the explored volume and the size of the binding area
(box dimensions 37.5 46.5 47.3 Å, centered in the inner cavity of
Cel-Pgp-1, at the point x ¼ 22.2 Å; y ¼ 77.6 Å; z ¼ 1.4 Å). For each
ligand conformer, 100 independent calculations were performed
using the Lamarckian genetic algorithm. All the other parameters
were set at the default value.
The 100 generated poses were assigned a score calculated by
AutoDock that can be considered as an estimated free energy of
ligand binding (indicative of binding afﬁnity). They were then
clustered as a function of the closeness of their positions and
conformations with RMSD set at 2.0 Å, and ﬁnally ranked by their
binding score (for the best pose in the cluster). The results are
displayed in an energy scores histogram, which reproducibility
could be assessed by comparing docking calculations performed on
close ligand conformers, or on a truly duplicated calculation. As a
result, binding energies (positions of the best pose in each cluster of
the histogram) were found to fall within a range of 0.25 kcal/mol,
and the number of poses in a cluster within 10%. This gives an
indication of the accuracy of the histogram parameters in our series
of runs, i.e., the binding energies and the overall distribution of
clusters.
2.4. Data analysis
Different parameters and observables can be used in the inter-
pretation of docking data issued by AutoDock: binding energies (i.e.
docking scores), histogram bars energy range, proﬁle of the histo-
gram, and location of calculated positions in the protein structure.
The position of clusters in ﬁgures and tables corresponds to the
binding energy value of the lowest energy pose in the cluster. The
spreading of clusters in the energy scores histogram was consid-
ered as a general indication for ligand docking calculation reli-
ability: the less scattered the energies, the higher speciﬁcity of
binding can be expected. Conversely, a pseudo-Gaussian proﬁle for
a group of histogram bars may suggest a non-speciﬁc docking.
However, in some cases, very negative binding energies (i.e. very
good docking scores) were found in poorly populated clusters
whereas the general aspect of the histogram was scattered. We
considered these poses as relevant, despite the lack of sampling, in
view of the gap energy with the next clusters, revealing high
binding site speciﬁcity.
The question arose as to whether the lowest energy cluster or
the most populated cluster (highest histogram bar) had to be
considered. The AutoDock docking score is based on an empirical
free-energy force ﬁeld which has been parameterized using a large
number of protein-inhibitor complexes for which both structure
and inhibition constants were known, and thus should reliably
reﬂect the afﬁnity of the ligand for the receptor, and the stability of
the ligand-protein complex. In contrast, the number of poses found
in a cluster reﬂects the number of times that conformers are found
in very close (within RMSD) binding sites, without any anticipation
of their stability. Thus considering the highest cluster in the energy
histogram may be not relevant per se for identifying the most
M.A. David et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 299e313302probable docking site of the considered ligand. Practically, for each
ligand, when the difference in the energies between the two best-
scored clusters was more than 2 kcal/mol, the lowest energy one
was considered as the most representative, since the other ones
correspond to ligand-protein complexes associated to negligible
lifetime. Alternatively, when the energy gap was narrower, we
manually analyzed all the clusters within 2 kcal/mol below the
lowest one for the localization of the included poses in the protein
3D structure. Finally, one or two main clusters were selected as
representative, and they corresponded most often to the ﬁrst and
second minimum energy clusters, except when clusters corre-
sponding to non-relevant positions in the protein were found
interleaved in the ranking. In some cases, this protocol of validation
led us to consider a double binding site on the protein, leading to a
stoichiometry of one or two depending on whether these two
docking positions were partially overlapping or not. Such a possi-
bility simply reﬂects the large size of the multispeciﬁc binding
domain, which likely encompasses the whole “inner chamber”.
Lastly, criteria for discriminating relevant from non-relevant
docking poses had to be deﬁned. This delineation was made
necessary by the fact that we enlarged the zone of docking search to
the whole membrane part of the protein. The large size of the grid
box ensured an exhaustive conformational exploration not biased
by preliminary beliefs, although it contributed to the scattering of
the docking results. Poses that were outside of the expected ligand
binding pocket were not considered for further analysis. These
were essentially poses located either “outside” of the Cel-Pgp-1
structure, i.e., at the protein/lipid interface, or lowermost in the
transmembrane domain, i.e., at the level of interface with the
cytosolic medium (“cytosolic antechamber”), where the phospho-
lipid polar headgroups are likely to be invaginated into the cavity
between the transmembrane helices in the inward-facing Cel-Pgp-
1 conformation (Haubertin et al., 2006). These poses can have a
functional relevance, for example as allosteric modulator sites, or
not, but likely not as binding sites for transport. Finally, a search of
the possible access channels allowing ligands to reach the inner
pocket was performed using Mole 2.0. (http://mole.upol.cz/). In
addition to the wide opening of the protein towards the cytosolic
interface, the result showed two lateral tunnels located between
TM10 and TM12, communicating with the cytosolic leaﬂet of the
membrane (data not shown).
For each lowest energy pose of selected clusters, the number
and nature of interacting residues were analyzed within the pro-
tein. Among these, particular interest was given to residues
belonging to the “hotspots for drug binding”, described hereafter.
2.5. Determination of the residues constituting the “hotspots for
drug binding”
A number of experimental works have been conducted in order
to determine the key residues responsible for multidrug recogni-
tion by mammalian Pgp (human and rodent isoforms). They
initially included various directed-mutagenesis analyses that
allowed identiﬁcation of residues whosemutation led to alterations
of the MDR proﬁle, in contrast to numerous mutations that led to
unspeciﬁc global decrease of Pgp function. The signiﬁcance of these
mutations was shown by cytotoxicity assays, which were a good
indication of their involvement in the multi-speciﬁc drug recog-
nition and binding. Furthermore, some additional data were
collected with a chemical cross-linking approach, using a few drug
derivatives bearing a moiety that could be activated, and ensuring
speciﬁcity by testing protection by the native drug. All these data
have been compiled in a review by Shilling et al. (2006), and were
completed by including some references by Loo& Clarke (Bessadok
et al., 2011; Loo et al., 2006a, b; Loo and Clarke, 2001, 2002). Finally,the only crystal structures released so far for mammalian Pgps are
of murine Pgp. They were co-crystallized with hydrophobic cyclic
peptide inhibitors than can be considered as functionally relevant
ligands, and which pointed to a set of contact residues. However,
two versions of the interpretation of the experimental X-ray
diffraction data have been published (Aller et al., 2009; Li et al.,
2014) that differed in the orientation of some transmembrane he-
lices and side chains. Therefore, we consider the lists of contact
residues from the two versions equally. All these identiﬁed residues
form a collection of 62 residues listed in Suppl. Table S1 with their
corresponding numbering in the 4 mammalian proteins sequences
(Hsa-ABCB1, Mmu-ABCB1a and B1b, Cgr-ABCB1). Moreover, 14 of
these 62 residues are common between at least two different
techniques. They are all situated in the transmembrane part of the
protein. Altogether, they provide a frame in the inner chamber that
offers a set of anchoring points for multi-speciﬁc recognition and
binding, and eventual translocation, of various transport ligands.
Multiple protein sequence alignments have been performed on
Cel-Pgp-1, human ABCB1, murine ABCB1a and B1b, and Chinese
hamster ABCB1, using Muscle software (Edgar, 2004). We checked
that the transmembrane segments were satisfactorily aligned.
Among the 62 human ABCB1 hotspot residues, 16 (26%) were found
identical and 12 homologous with the corresponding residues in
Cel-Pgp-1, representing a global conservation ratio of 45%. As a
comparison, human ABCB1 and Cel-Pgp-1 display a global simi-
larity of 63% (BLASTP positive matches), and still 58% when
considering the TMDs only. This indicates that hotspots are sub-
jected to more genetic variation than the overall sequence. More
precisely, this set of residues is mainly hydrophobic, but less
markedly for Cel-Pgp-1: the hydrophobic (F-Y-A-L-I-V-M)/hydro-
philic (S-T-N-Q-H) ratio is 44/14 for Hsa-Pgp and 37/20 for Cel-Pgp-
1, respectively.
3. Results
3.1. Binding mode of macrocyclic lactones on Cel-Pgp-1
We have ﬁrst docked seven ML of pharmacological interest,
whose structures are presented in Suppl. Fig. S1. A model for the
binding site of ivermectin (IVM), and four other avermectins, aba-
mectin (ABA), eprinomectin (EPR), doramectin (DOR) and sela-
mectin (SEL), the ivermectin-aglycone derivative (IVA), and the
milbemycin, moxidectin (MOX) on Cel-Pgp-1 was hence proposed.
The energy clustering histograms obtained from the docking
calculations allowed us to identify two major possible positions for
each ML (except one for DOR), based on the lowest (i.e. most
negative) binding energies calculated (Fig. 1A and Suppl. Fig. S2)
that were considered relevant for predicting ML binding site. The
binding energies for all the considered clusters (13 for the 7 ML)
ranged from 13.0 to 9.4 kcal/mol, which are indicative for high
afﬁnity binding to Cel-Pgp-1. All positions were found in the Cel-
Pgp-1 deepest part of the inner transmembrane cavity, at the top
of the inner chamber, and the identiﬁcation of drug interacting
residues, some forming H-bonds, allowed us to delineate a speciﬁc
ML binding site, which involved several amino acids identiﬁed as
hotspot residues on mammalian Pgp (detailed in Table 2 and
Suppl. Table S2).
3.1.1. Docking of avermectins and the milbemycin, moxidectin
For IVM, the positions of the two lowest energy clusters on Cel-
Pgp-1 were very close, with IVM1 (12.2 kcal/mol, 20 poses) being
slightly deeper in the inner chamber than IVM2 (11.1 kcal/mol, 6
poses) (Table 1 and Fig. 1). Overall, they interacted with 19
(including 14 hotspot residues, 2 H-bonds) and 13 residues (6
hotspot residues, 3 H-bonds), respectively, and they shared 6
Fig. 1. Ivermectin and moxidectin binding to Cel-Pgp-1. A and B. Histograms of energy scores, clusterized at RMSD ¼ 2 Å. The ﬁrst (1) and second (2) lowest energy clusters are
framed with red and green dotted lines, respectively. C and D. Binding sites of the lowest energy clusters of IVM (C) and MOX (D). E and F. Binding sites of the 2nd lowest energy
clusters of IVM (E) and MOX (F). IVM is represented in red spheres, MOX is represented in green spheres, Cel-Pgp-1 in light blue (N-term) and yellow (C-term) ribbon. Images were
generated using PyMol. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article).
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1 H-bond (Table 2 and Suppl. Table S2).
For ABA, the two lowest-energy positions identiﬁed (12.3
and11.1 kcal/mol, 8 and 37 poses, respectively) interacted with 21
and 15 residues, including 17 and 10 hotspot residues, respectively,
and forming 2 H-bonds (Table 1). They shared 8 common inter-
acting residues (including 6 hotspot residues and 0 H-bond) that
closely overlappedwith IVM positions (Table 2 and Suppl. Table S2).
For EPR, the clustering was more scattered than that of ABA orIVM (Suppl. Fig. S2), but nevertheless two lowest energy clusters
were found at 12.5 kcal/mol (EPR1, 7 poses) and 12.0 kcal/mol
(EPR2, 6 poses) (Table 1). They both bound in the deep pocket in the
inner chamber, with EPR2 being deeper than EPR1. These two
clusters interacted with 14 and 12 hotspot residues (6 were shared
by both positions), respectively, among 20 and 17 interacting resi-
dues (8 shared), and formed 1 and 2 H-bonds, respectively (Table 2
and Suppl. Table S2).
For DOR, only one energy cluster was considered (13.0 kcal/
Table 1
Physico-chemical properties and docking characterization of macrocyclic lactones to Cel-Pgp-1: ivermectin (IVM), abamectin (ABA), eprinomectin (EPR), doramectin (DOR),
selamectin (SEL), ivermectin-aglycone (IVA) and moxidectin (MOX).
Molecule IVM ABA EPR DOR SEL IVA MOX
MW (Da) 875 873 914 899 770 587 640
logP 4.3 4.4 4.2 4.7 5.2 3.4 5.4
Cluster rank 1 2 1 2 1 2 1 1 2 1 2 1 2
Binding Energy (kcal/mol) 12.2 11.1 12.3 11.1 12.5 12.0 13.0 12.9 12.4 9.6 9.4 10.5 10.1
Nb of poses 20 6 8 37 7 6 19 52 23 33 49 6 68
Nb of inter-acting residues 19 13 21 15 20 17 17 14 18 10 10 19 16
Nb of hotspot residues 14 6 17 10 14 12 14 13 12 7 8 14 8
Nb of H-bonds 2 3 2 2 1 2 1 2 2 3 2 3 2
Table 2
List of interacting residues of each transmembrane helix of Cel-Pgp-1 with the ﬁrst or second lowest energy clusters of ivermectin (IVM1), abamectin (ABA1), eprinomectin
(EPR1), doramectin (DOR1), selamectin (SEL2), ivermectin-aglycne (IVA2) andmoxidectin (MOX2). Bold: hotspot residues. Underscored: residues establishing a H-bond. Black:
residues interacting with macrocycle. Red: residues interacting with benzofurane. Blue: residues interacting with spiroketal unit. Green: residues interacting with the mono/
di-saccharide moiety.
Molecule  IVM ABA EPR  DOR SEL  IVA  MOX  
Cluster 
Rank  1st 1st 1st 1st 2nd 2nd 2nd 
TMa-b  
E22 E22 E22 E22 
D23  
K26  K26  
TM1 
L91 L91 
M94 M94 M94 
Q98 Q98 Q98 Q98 
TM5 F334 
TM6 
L356 L356 
F359  F359 F359 F359 
S360  S360 S360 S360 
M363  M363 M363 
M364 M364 M364 
M367 M367 M367 M367 
L371 
TM7 Y771  Y771 Y771 
F775  F775  F775 F775 
TM10 
L906 L906 L906 L906 
V909  V909 V909 V909 V909  V909
A910  A910 A910 A910
G912 G912 
Q913  Q913 Q913 Q913 Q913 Q913  
R916 R916 R916 
TM11 
A986 A986 A986 A986 
S987 S987 S987 
V989 V989 V989 V989 
L990 L990 L990 L990 L990 L990 L990 
L993 L993 
N994 N994  
Y998   
TM12 
M1021
Y1022  Y1022 Y1022 Y1022   Y1022  
T1025  T1025 T1025 T1025 T1025  T1025
I1026 I1026 I1026 
T1028 T1028 T1028 T1028 T1028 T1028 T1028 
 S1029  S1029 S1029  
L1031 
G1032 
 F1033  
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the other clusters (Suppl. Fig. S2). DOR1 interacted with 17 residues
in Cel-Pgp-1 transmembrane inner chamber, including 14 hotspotresidues, with 1 H-bond formed (Table 2 and Suppl. Table S2).
For SEL, the two lowest energy clusters were found
at 12.9 kcal/mol (SEL1, 52 poses), and 12.4 kcal/mol (SEL2, 23
Fig. 2. Binding domain characteristics of macrocyclic lactones. A. Front view of Cel-
Pgp-1 represented in transparent light blue (N-term) and yellow (C-term) ribbon, with
the binding sites of the ﬁrst and second lowest energy clusters of abamectin (ABA1 and
ABA2, black), ivermectin (IVM1 and IVM2, red), eprinomectin (EPR1 and EPR2, sand),
doramectin (DOR1, blue), selamectin (SEL1 and SEL2, purple), ivermectin-aglycone
(IVA1 and IVA2, orange), and moxidectin (MOX1 and MOX2, green), all represented
in sticks and transparent surfaces. TM helices numbers are indicated as their number
only, on each helix. B. Zoom, without Cel-Pgp-1, on the front and lateral views of the
overlap between the binding sites of the ﬁrst lowest energy clusters of abamectin
(ABA1, black), ivermectin (IVM1, red), eprinomectin (EPR1, sand), doramectin (DOR1,
blue). C. Zoom, without Cel-Pgp-1, on the front and lateral views of the overlap be-
tween the binding sites of second lowest energy clusters of selamectin (SEL2, purple),
ivermectin-aglycone (IVA2, orange), moxidectin (MOX2, green), with the lowest en-
ergy cluster of ivermectin (IVM1, red) as a marker of the binding position of other ML.
All molecules are represented in sticks. Images were generated with PyMol. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article).
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other, with 14 and 18 interacting residues, 13 and 12 being hotspot
residues, respectively. They each formed 2 H-bonds with different
hotspot residues, and they shared 8 common interacting residues,
including 7 hotspot residues (Table 2 and Suppl. Table S2).
For IVA, the two lowest energy clusters together comprising
most of the poses (82%), indicating a good speciﬁcity of binding to
this site, were close in energy, at 9.6 and 9.4 kcal/mol, and both
bound very similarly to a unique binding site (Table 1). IVA1 and
IVA2 shared 6 common interacting residues out of 10 for each, with
4 hotspot residues out of 7 and 8, respectively, and formed 3 and
2 H-bonds, respectively (Table 2 and Suppl. Table S2).
For MOX, the two lowest energy clusters were found
at 10.5 kcal/mol (MOX1, 6 poses) and 10.1 kcal/mol (MOX2, 68
poses) (Table 1 and Fig. 1). They interacted with 19 and 16 residues,
8 being common to the 2 clusters, including 14 and 8 hotspot res-
idues, respectively; 5 of which being common and forming 3 and
2 H-bonds, respectively (Table 2 and Suppl. Table S2).
In summary, the very low binding energies calculated in the
docking modes (from 13.0 to 11.1 kcal/mol), strongly suggest
that avermectins can bind with high afﬁnity to Cel-Pgp-1 (Table 1).
IVA and MOX positions showed signiﬁcantly less negative binding
energies (from 10.5 to - 9.4 kcal/mol) than the avermectins,
reﬂecting a lower afﬁnity, but they were still consistent with spe-
ciﬁc binding to Cel-Pgp-1. Interestingly, all ML comparably bound
to a unique site located deep in the transmembrane domain of the
nematode transporter, and subtle differences were observed in
relation with the speciﬁc substituents of each ML (Table 2).
3.1.2. Relation between ML structure and their binding
characteristics
We showed above that all ML bound to a similar and speciﬁc
binding site (Fig. 2A) on the transmembrane domain of Cel-Pgp-1,
with very negative energies reﬂecting high afﬁnity binding
(Table 1). In addition, ML binding involved some hotspot residues,
which have been previously identiﬁed to be important for drug
binding to mammalian Pgp (Table 2 and Suppl. Table S2). Never-
theless, it was possible to point out noticeable speciﬁcities between
each ML, due to their different substituents that appeared impor-
tant in the respective orientation of each ML in their binding site.
Thus, we could propose several common features and some speciﬁc
aspects for eachML in terms of binding characteristics, based on the
analysis of their two lowest energy clusters.
3.1.2.1. Inﬂuence of the macrocyclic ring. The docking of each ML on
Cel-Pgp-1 revealed that a total of 42 residues interacted with ML
(Table 2). Among them, 14 residues, including 10 hotspot residues,
were found to interact at least 5 times when considering the 10
most clearly overlapping cluster positions, which delineated a
speciﬁc binding pocket, and gave a speciﬁc “ﬁngerprint” for ML
binding (Table 2 and Suppl. Table S2). Remarkably, the followingML
cluster positions: IVM1, ABA1, EPR1, DOR, SEL2, IVA2 and MOX2
tightly superimposed (Fig. 2B and C), and they aligned quite
perfectly at the macrocyclic ring level. Therefore, the binding
characteristics of these relevant clusters were further analyzed. In
particular, the residues E22, M367 and L990 were respectively
interacting with the C12e13, C14e15 and C17-18 of the macrocyclic
ring: interactions of E22 with IVA and MOX; M367 with ABA, IVA
and MOX; and L990 with DOR, SEL and IVA (black colored in
Table 2).
3.1.2.2. Inﬂuence of the benzofurane moiety. The benzofurane moi-
ety is also a common structural feature that superimposed for all
ML on their binding site in Cel-Pgp-1, although it was found in an
inverted orientation for SEL and IVA when compared to the otherML. Indeed, in most of the tested ML, the benzofurane moiety
interacted with 6 residues, i.e. L906, V909, A910, L990, T1028 and
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T1028 on TM12, and in all the considered cluster positions, the C5-
hydroxyl group formed an H-bond with T1028 (Table 2 and Fig. 3).
T1028 has also been identiﬁed as a hotspot residue, and therefore
we considered it as an important factor for the binding of all ML.3.1.2.3. Inﬂuence of the spiroketal moiety. The spiroketal moiety,
commencing at C17, differs between ML in various ways, and it
introduces stereochemical diversity that impacts the binding to
Cel-Pgp-1. ABA (an avermectin B1) is the natural compound from
which most of avermectins are derived, and it has a C22eC23
double bond instead a saturated bond for IVM (C22eC23 dihydro-
avermectin B1). Consequently, the spiroketal moiety of ABA has
higher structural rigidity, and it bound to Cel-Pgp-1 in a slightly
different orientation than that of IVM (Fig. 2B); both sharing only
one common interacting residue (blue colored in Table 2). This
reveals that the saturation of the C22-23 bond played a role in the
conformation of the ML, and impacted the binding characteristics
of the IVM spiroketal moiety. EPR (40-epiacetylamino-40-deoxy-
avermectin B1) differs from ABA at the spiroketal moiety level by
having at C25 a terminal oleandrose group. Nevertheless, the spi-
roketal moieties of EPR and ABA matched strictly on their binding
site (Fig. 2B), interacting with residues mainly present on TM10
(Q913, R916) and TM11 (A986, S987, V989, L990) (Table 2). MOX has
a substituted oleﬁnic side chain at the 25-position and aFig. 3. Key residues of Cel-Pgp-1 for interaction with macrocyclic lactones. A and B. Cel
(IVM1, red lines) (A) and moxidectin (MOX2, green sticks) (B). Cel-Pgp-1 is represented in lig
speciﬁcally interacting residues. Atoms of Cel-Pgp-1 residues and substrates are colored in b
red shadow. C and D. Ivermectin (C) and moxidectin (D) plane structures with H-bonds to res
interpretation of the references to colour in this ﬁgure legend, the reader is referred to themethoxime group at the 23-position, which are two characteristics
speciﬁc to this drug, not found in other commercial milbemycins or
avermectins. Remarkably, although the spiroketal moieties of MOX,
DOR, ABA and EPR differ considerably (Suppl. Fig. 1), the sub-
stituents bound to the same binding site with similar orientation
for the four drugs (Fig. 2B and C), interacting with TM10 and TM11,
and sharing Q913, A986 and V989 as common interacting residues
(Table 2). Conversely, although DOR and SEL have similar spiroketal
moieties characterized by a C25-cyclohexyl substituent, they did
not overlap on the Cel-Pgp-1 binding site (Fig. 2 B and C). SEL and
IVA have also similar spiroketal moieties that are both partly
aligned with the disaccharide group of the four di-glycosylated
avermectins (Fig. 2 B and C), interacting partly with TM11 and
partly with TM12 (Table 2). This clearly revealed that common
structural features, other than the spiroketal moiety, determine the
orientation of ML on the binding site. This could be the presence of
one or two sugars, or the saturated bond on C22-23 in SEL and IVM.3.1.2.4. Inﬂuence of the disaccharide moiety. The four avermectins
IVM, ABA, EPR and DOR have in common a disaccharide moiety
linked to the C13 of the macrolide. This substituent mostly super-
imposed for these four ML (Fig. 3B), and interacted with TM1, TM6,
TM7 and TM12 (green colored in Table 2). They all shared a number
of interacting hotspot residues, i.e. F359, S360, F775 and Y1022,
plus Q98, M363, M364, Y771, T1025 and I1026 when considering-Pgp-1 key residues surrounding the binding site or forming H-bonds with ivermectin
ht blue (N-term) and yellow (C-term) transparent ribbons for TM helices and sticks for
lue for N, red for O and grey for H. H-bonds are represented in yellow dotted lines with
idues of Cel-Pgp-1 represented as dotted lines. Images were generated with PyMol. (For
web version of this article).
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speciﬁc of di-glycosylated avermectins. Interestingly, ABA and IVM
disaccharide moieties both formed an H-bond with the hotspot
residue Y771, showing the importance of this residue in the
orientation of ML that contain a disaccharide (Table 2 and Fig. 3A
and C). Apart from Y1022 and T1025, which interacted with spi-
roketal or benzofurane, none of the residues listed above interacted
with IVA and MOX. Given the absence of glucide substituent on
these two ML, and the monosaccharide of SEL, these residues are
interacting speciﬁcally with the distal sugar unit of the dis-
accharidic avermectins. Indeed, the orientation of the mono-
saccharide of SEL and the hydroxyl on the C13 of IVA superimposed
in a different orientation than that of the corresponding structure
of other ML, which overlapped with the spiroketal moiety of IVM,
and shared with it the residues E22 and K26 in TMa-b, and Q913 in
TM10 as common interacting residues (Fig. 2 and Table 2). Because
their only structural difference relies on the presence or absence of
disaccharide, the comparison of IVM and IVA binding provided
interesting information. Remarkably, 7 of the 10 residues interact-
ing with IVA1 were all found to interact with IVM1, with a common
H-bond on T1028, showing that the binding site of these two
closely related molecules are very similar (Suppl. Table S2). It
should be mentioned that the three ML lacking the disaccharide
(SEL, IVA and MOX) exhibited an energetic clustering clearly less
scattered than the four di-glycosylated avermectins (see Fig. 1A and
Suppl. Fig. S2), suggesting that the absence of the two sugar units
signiﬁcantly increased the selectivity of the calculated interactions
with the recognition domain. In addition, the two unglycosylated
ML (IVA and MOX) have signiﬁcant higher (i.e. less negative)
binding energies when compared with other ML, which supports
the important role of sugar in anchoring IVM onto the binding site.
Globally, these data reveal that all ML bound with good energy
in the same pocket buried within the Cel-Pgp-1 inner chamber, and
were clearly superimposed. Consideration of the residues involved
in the binding of each chemical moiety of the ML, presented in
different colors in Table 2, clearly supports a typical and unique
binding pocket for all ML (Figs. 2 and 3). Furthermore, as the four
ML that contain a disaccharidemoiety were aligned for their lowest
energy clusters, while this happens only for the second clusters of
SEL, IVA and MOX, we propose that the main determinant of the
orientation of ML, in their binding pocket, is the disaccharide
moiety.
3.2. Binding mode of other anthelmintic drugs with Cel-Pgp-1
3.2.1. Docking results
The structures of all AHs tested are shown in Suppl. Fig. S3. For
predicting AH binding site, a similar approach was used to choose
the optimal cluster energy from the histogram obtained from the
docking calculations (Suppl. Fig. S4).
For triclabendazole (TCZ), the lowest energy cluster (TCZ1, 97
poses) appeared at 8.0 kcal/mol, whereas the only other clusterTable 3
Physico-chemical properties and docking characterization of anthelmintics to Cel-Pgp-1:
R), monepantel (MNP-S) and emodepside (EMD). IVM data from Table 1 are given in ital
Molecule TCZ TBZ LEV-R
MW (Da) 360 201 204
logP 5.8 2.2 2.9
Cluster rank 1 2 1* 2 1*
Binding Energy (kcal/mol) 8.0 7.4 7.2 5.7 6.8
Nb of poses 97 3 94 3 31
Nb of inter-acting residues 8 9 12 7 12
Nb of hotspot residues 8 6 3 6 5
Nb of H-bonds 1 1 0 2 1(TCZ2, 3 poses) was found at 7.4 kcal/mol (Table 3). On the one
hand, TCZ1 was found deep in the inner chamber of Cel-Pgp-1
(Fig. 4), interacting with 8 residues, (all hotspot residues, 1 H-
bond) (Table 4). On the other hand, the binding site of the second
cluster was in the middle of the inner chamber, at the level of the
middle of the transmembrane bilayer (Fig. 4). For this position, 9
interacting residues were found (6 hotspot residues, 1 H-bond)
(Table 4). These two positions were totally separated (Table 4 and
Fig. 4), hence consistent with a binding stoichiometry of 2.
For thiabendazole (TBZ), the lowest energy cluster (TBZ1, 94
poses) was at 7.2 kcal/mol (Table 3), but it was found at a very
lateral position in the TM helices of Cel-Pgp-1 (Fig. 4). TBZ1 inter-
acted with 12 residues (3 hotspot residues, no H-bond) (Table 4).
Alternatively, the second cluster (TBZ2, 3 poses), found at5.7 kcal/
mol, was found deep in the inner chamber, totally apart from TBZ1
(Fig. 4). It showed 7 interacting residues, (6 hotspot residues, 2 H-
bonds) (Table 4) and shared 5 common residues, including 4 hot-
spots, with TCZ1 (Table 4).
For levamisole (LEV), the lowest energy cluster, (LEV1, 31 poses)
of the two enantiomers R and S, which gave similar results for all
clusters, was found at6.8 kcal/mol (Table 3). It bound to Cel-Pgp-1
on a very lateral position in the TM helices bundle, close to TBZ1
position, and sharing 3 common interacting residues with TBZ1
(Table 4 and Fig. 4). LEV1 interacted with 12 binding residues (5
hotspot residues, 1 H-bond) (Table 4). The second lowest energy
cluster, LEV2 (65 poses), formed a cluster at6.1 kcal/mol (Table 3).
It interacted deep in the inner chamber, very differently from LEV1,
and overlapping with TCZ1 and TBZ2 (Fig. 4). It bound to 8 residues,
(7 hotspot residues, 2 H-bonds), and showed 7 common interacting
residues, including 6 hotspot residues, with TBZ2, and 5 common
interacting residues with TCZ1, all hotspot residues (Table 4) .
For closantel (CLO), similar lowest energy clusters CLO1 were
found whatever the enantiomer considered, S or R. For the latter, it
contained the maximum number of poses (80) at 10.3 kcal/mol
(Table 3 and Fig. 5A). The binding site of this cluster was in the
middle of the inner chamber (Fig. 5B), similar to the three other
clusters found between 9.5 and 9.9 kcal/mol, and showed 10
interacting residues (6 hotspot residues, 2 H-bonds) (Table 4). It
shared 3 common interacting hotspot residues with TCZ1, 2 with
TBZ2 and LEV2, as well as 2 common interacting residues with TCZ2
(Table 4 and Fig. 4).
For monepantel (MNP), two main docking positions were found
for both enantiomers S and R. For MNP-S, on one hand, the lowest
energy cluster (MNP1, 3 poses) was found at 8.1 kcal/mol
(Table 3), and bound “horizontally” at the level of the middle of the
bilayer (Fig. 4). The 2 following clusters docked at very similar
positions. On the other hand, the 4th cluster (MNP4, 1 pose)
showed an energy of 7.8 kcal/mol, and was very close to most of
the clusters LEV2, TBZ2 and TCZ2, at the deepest part of the inner
chamber (Fig. 4). They both interacted with 14 residues, including 6
hotspot residues and 1H-bond for MNP1, and 12 hotspot residues
without forming any H-bond forMNP4 (Table 3). These two bindingtriclabendazole (TCZ), thiabendazole (TBZ), levamisole-R (LEV-R), closantel-R (CLO-
ic for the sake of comparison. (*) cluster positioned outside the inner chamber.
CLO-R MNP-S EMD IVM
663 473 1119 875
7.6 5.6 7.3 4.3
2 1 1 4 1 1 2
6.1 10.3 8.1 7.8 9.5 12.2 11.1
65 80 3 1 5 20 6
8 10 14 14 17 19 13
7 6 6 12 6 14 6
2 2 1 0 3 2 3
Fig. 4. Binding domains of anthelmintic drugs. A. Front view of Cel-Pgp-1 repre-
sented in transparent light blue (N-term) and yellow (C-term) ribbon, with the binding
sites of the ﬁrst and second lowest energy clusters of triclabendazole (TCZ1 and TCZ2,
light pink), thiabendazole (TBZ1 and TBZ2, purple), levamisole-R (LEV1 and LEV2, dark
green), closantel-R (CLO1, yellow), monepantel-S (MNP1 and MNP4, light green),
emodepside (EMD1, dark blue), all represented in sticks and transparent surfaces. TM
helices numbers are indicated as their number only, on each helix. B. Zoom, without
Cel-Pgp-1, on the front view of all anthelmintics docking positions in the binding sub-
domains, represented in transparent surfaces. C. Zoom, without Cel-Pgp-1, on the front
and lateral views of the overlaps between the binding sites of triclabendazole (TCZ1
and TCZ2, light pink), thiabendazole (TBZ2, purple), levamisole (LEV2, dark green),
closantel (CLO1, yellow), monepantel (MNP1 and MNP4, light green) and emodepside
(EMD1, dark blue). All molecules are represented in sticks. Images were generated with
PyMol. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article).
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chiometry of 2. In addition, MNP1 shared 9 common interacting
residues with TCZ2 and 2 with CLO1. MNP4 shared 7 common
interacting residues with TCZ1 and TBZ2, 8 with LEV2, and 4 with
CLO1 (Table 4 and Fig. 4).For emodepside (EMD), the lowest energy cluster (EMD1, 5
poses) was found at 9.5 kcal/mol (Table 3). Its docking position
was found near the cytosolic aperture of the inner chamber (Fig. 4).
EMD1 bound to 17 residues (6 hotspot residues, 3 H-bonds)
(Table 4), and shared 4 interacting residues with CLO1, 1 with TCZ2,
and 2 with MNP1. All the other clusters bound very closely to the
same site.
3.2.2. Analysis of the binding sites of AHs
The binding domain in Cel-Pgp-1 for AHs belonging to different
classes could be analyzed by comparing their respective interacting
sites and residues (Table 4 and Fig. 4). First, the two benzimidazoles,
TCZ and TBZ, as well as the imidazothiazole LEV, displayed docking
positions (TCZ1, TBZ2 and LEV2) that were remarkably highly
overlapping (Table 4 and Fig. 4): they shared 5 common interacting
residues (Q98, N994, M1021, Y1022, T1025), all hotspot residues.
Their related chemical structures and small sizes made possible
their interaction with the deepest part of the inner chamber of Cel-
Pgp-1.
Second, this inner sub-domain is not speciﬁc to the structurally
related AHs, TCZ, TBZ and LEV, since CLO1 and MNP also bound on
it. Nevertheless, with its two binding positions, MNP, along with
CLO1 and TCZ2, can describe a bigger surface of the inner chamber
by ﬁlling various connected sub-sites (Fig. 4). Therefore, in the core
of the chamber, the three AHs, TCZ, CLO and MNP share a high
number of common interacting residues with IVM (taken as the
representative molecule for all ML, gathering IVM1 and IVM2): 8
(including 7 hotspot residues) for TCZ1 & TCZ2, 8 (including 5
hotspot residues) for CLO1, and 9 (including 6 hotspot residues) for
MNP1 and MNP4 (Table 4).
Finally, the large molecule EMD was well accommodated by the
binding sub-domain close to the cytoplasmic entrance of the inner
chamber of Cel-Pgp-1. Indeed, it also shared some common inter-
acting residues with MNP1, TCZ2 and CLO1 (Fig. 4). Moreover,
among its 17 interacting residues found in the docking, 9 (including
5 hotspot residues) were common to IVM1 and IVM2 (Table 4).
4. Discussion
Resistance against anthelmintic drugs in parasite nematodes,
including against ML, compromises the therapeutic beneﬁt of AH-
based treatments (Lespine et al., 2012). Taking account of the
serious concern for animal and human health caused by nematode
infections, it is urgent to gain an understanding of the molecular
factors involved in limiting drug efﬁcacy in nematodes. It is now
well established that some ABC transporters are central in limiting
ML efﬁcacy. Mammalian Pgp transports ML out of the host organ-
ism thereby limiting the active concentration reaching the nema-
tode target (Kiki-Mvouaka et al., 2010). In addition, some nematode
Pgps also interact with ML, and they are involved in the process of
development of AH resistance (Lespine et al., 2012). Nevertheless,
tools are needed to understand in detail the role of these proteins in
ML transport, and to consider them as relevant targets for reversion
of AH resistance. The release of the 3D crystal structure of Cel-Pgp-
1, with good resolution (Jin et al., 2012) and QMEAN Z-score
(Domicevica and Biggin, 2015) provides an opportunity to launch a
sound in silico structural study of drug binding to this protein. This
is particularly relevant in the view of multispeciﬁc recognition, and
hence expected transport capacity, of this model protein. Indeed,
the open inward-facing conformational state, in which Cel-Pgp-1
has been crystalized as revealed by the study of Jin et al. (2012),
is by far the most frequent found conformation among the ABC
proteins structurally determined today (Ward et al., 2007), and
particularly the unique one found for mammalian Pgps (Aller et al.,
2009; Li et al., 2014; Szewczyk et al., 2015). This conformation
Table 4
List of interacting residues of each transmembrane helix of Cel-Pgp-1with the selected lowest energy clusters of triclabendazole (TCZ), thiabendazole (TBZ), levamisole-R (LEV-
R), closantel-R (CLO-R), monepantel-S (MNP-S) and emodepside (EMD). The interacting residues with the reference ML, ivermectin (Table 1), are also presented for com-
parison. Bold: hotspot residues. Underscored: residues establishing a H-bond. Green: common interacting residues to TCZ1. Blue: common interacting residues to TCZ2.
Orange: common interacting residues to TBZ1. Dark green: common interacting residues to TBZ2. Purple: common interacting residues to LEV2. Brown: common interacting
residues to CLO1. Pink: common interacting residues to MNP1. Black: interacting residues never shared with any other AH cluster.
Molecule TCZ TBZ LEV-R CLO-R MNP-S EMD IVM 
Cluster 
Rank 1st 2nd 1st 2nd 1st 2nd 1st 1st 4th  1st 1st 2nd 
TMa-b 
11L
R12 
P21 
E22 
D23 
L25 L25
K26  K26 K26 
I29 
K30 
    E33             
TM1 L91 L91Q98 Q98 Q98 Q98 
TM3 Q219 Q219  Y220  Y220 Y220
TM5 Q327 
TM6
F359 F359 
S360 
M363 M363 
M367
G370
L371 L371
           P374  
TM7
G764
Y768 
Y771 Y771 Y771 
F775 F775 
TM8
 Q807               
C810
S811
 M814               
TM9
R873 
T876 T876
V877 
T879
T880 T880 
TM10
L906 L906  L906
V909 V909 V909 V909 V909
A910 A910 A910 
Q913 Q913 Q913 Q913 Q913 Q913 
R916 R916
           G917      
TM11
       Y983     
A986 A986
S987 S987
V989 V989
L990 L990 L990 L990 
Y991 Y991 
L993 L993 L993
N994 N994 N994 N994
A997 A997 A997
Y998 Y998 Y998
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to be the competent one for substrate recognition and uptake. This
is corroborated by the fact that the only Pgp structures co-
crystalized with a drug involve Mmu-Pgp with QZ59 derivatives,
all bound in the same location within the inner chamber. From all
the structures today available, either from bacterial or eukaryotic
organisms, the general scheme admitted for drug translocation by
multidrug transporters implies that the initial drug chelation step,obviously necessary for drug transport, occurs before and inde-
pendently from the following trans-conformational steps consti-
tuting the catalytic cycle of the active ATP-dependent
transmembrane drug translocation.
However, a critical point is that our in silico approach needs to be
validated by an in silico/in vitro correlation. Such a validating cor-
relation could actually be achieved by considering the enzymatic
data reported in the same publication (Jin et al., 2012) and a series
Fig. 5. Closantel-R binding to Cel-Pgp-1. A. Histogram of energy scores, clusterized at
RMSD ¼ 2 Å. The lowest (1) energy cluster is framed with red dotted lines. B. Binding
site of the lowest energy cluster, generated using PyMol. Closantel-R is represented in
light yellow spheres, Cel-Pgp-1 in light blue (N-term) and yellow (C-term) ribbon. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article).
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that have been shown to stimulate Cel-Pgp-1 ATPase activity,
compared to a negative control without effect on this activity. This
previous analysis allowed us to draw the conclusion that the inner
chamber of Cel-Pgp-1 should be considered as the binding domain
competent for recognizing transport substrates, thereby initiating
the active transport cycle leading to their transmembrane trans-
location. We have thus deﬁned a threshold value for binding en-
ergies between “ligands” and “weak- or non-ligands”, at about 4
to 5 kcal/mol (David et al., work in process).
Finally, since the inner chamber is in direct connection with the
lipid phase of the surrounding membrane, it can be expected to be
ﬁlled with phospholipid molecules when considering the limits of
the hydrophobic thickness of the protein and its positioning in the
bilayer calculated by the OPM server (http://opm.phar.umich.edu).
In a ﬁrst approximation, the lipid phase can be considered as ﬂuid,
so that, similarly to solvent molecules, lipid molecules are not
considered as ligands bound to the protein, and thus not included
in the grid maps calculated by Autodock. Lipids are rather expected
to inﬂuence the kinetics of interaction but not the drug bindingafﬁnity for the receptor at equilibrium. However, in a multispeciﬁc
context, the speciﬁc binding of lipids cannot be excluded. If such
speciﬁc lipid binding site exists, with an afﬁnity comparable to the
considered drug, possible competitive interactions can occur be-
tween drug and lipid, depending on the location of the corre-
sponding binding sites within the multispeciﬁc inner chamber. The
scope of this study is nevertheless to model and analyze possible
AH drugs interactions with Cel-Pgp-1 in a pharmacological
perspective.
4.1. Structural characterization of the ML binding site in Cel-Pgp-1
For the ﬁrst time, our docking data provides strong evidence
that Cel-Pgp-1 is involved in ML high afﬁnity recognition and
eventual active transport. All the tested ML displayed very low
binding energies (between 13.0 and 9.4 kcal/mol), in the range
of binding energies found for the set of validation ligands, as dis-
cussed elsewhere (David et al., work in process). Thewhole docking
data collected on seven ML revealed a striking homogeneity in the
predominant bound conformations found, in favor of a very similar
binding mode for all of themwithin the inner chamber of Cel-Pgp-
1. This convergence is indicative of the robustness of the docking
results and contributes to give them high conﬁdence.
Remarkably, all ML were bound in the most buried part of the
transmembrane inner chamber. More speciﬁcally, the macrocycle
and the benzofurane moieties, which together constitute the
common core of the ML chemical structures, always clearly
superimposed in the same sub-sites. In particular, the hotspot
residue T1028 was found to establish various H-bonds with ben-
zofurane groups of all tested ML. At variance, the spiroketal moiety,
also present in all ML, proved to be able to accommodate two
distinct sub-sites in the same area, suggesting possible alternate
binding modes for this substituent. More noticeably, all the con-
formations found for the 7 tested ML involved a high ratio of hot-
spot residues: indeed, over the 13 considered docking positions, a
total of 209 interacting residues were detected by AutoDock, of
which 149 (about 70%) were hotspot residues. This emphasizes a
possible underlying structural homology with mammalian Pgp for
binding large amphiphilic/hydrophobic ligands.
Regarding the disaccharide moiety harbored by four of the
tested avermectins (ABA, IVM, EPR, DOR), the comparison with the
data obtained with SEL (bearing one monosaccharide), IVA and
MOX (no sugar unit), highlighted the effects of a sugar moiety on
binding afﬁnity for Cel-Pgp-1. First, SEL displayed binding energies
(12.9/-12.4 kcal/mol) typically within the range of values calcu-
lated for the other tested avermectins (13.0 to 11.1 kcal/mol),
whereas IVA and MOX clearly displayed less favorable binding
energies (10.5 to 9.4 kcal/mol). This indicates that the proximal
sugar unit plays a major role in establishing energetic interactions
with the receptor binding domain, while the distal sugar is less
inﬂuential in stabilizing the interaction. This is reinforced by the
signiﬁcant number of hotspot residues (13) on Cel-Pgp-1 interact-
ing with the sugar moiety. Second, SEL, IVA andMOXwere all found
in two overlapping but distinct docking positions, both relevant
since they correspond to their two lowest energy clusters. One
position overlaid well with that of the four disaccharide-branched
avermectins, whereas the other one, although still in the same
sub-site, was oriented differently. Although highlighting the
remarkable common binding mode of all the tested ML, these data
also illustrate the role of the disaccharide moiety in anchoring ML
in the summit part of the inner chamber in Cel-Pgp-1, in which it is
well ﬁtted due to favorable steric interactions.
Our data are consistent with reports showing interactions be-
tween ML and C. elegans Pgps, with increased Cel-Pgp-1 expression
in IVM-resistant C. elegans strains (James and Davey, 2009; Yan
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Prichard, 2013; Janssen et al., 2013) and MOX (Bygarski et al., 2014)
after disruption of the Cel-Pgp-1 gene. In addition, major differ-
ences have been reported on interaction of IVM and MOX with
mammalian Pgp. Indeed, the apparent afﬁnity of IVM for Cgr-Pgp
calculated in vitro was higher than that of MOX (Lespine et al.,
2007; Prichard et al., 2012), and disaccharide moities were then
suggested to modify the binding property of ML. Similarly, both
drugs interact differently with parasitic nematode Pgps (Godoy
et al., 2015a, 2015b, 2016; Kaschny et al., 2015; Kerboeuf and
Guegnard, 2011; Mani et al., 2016). Thus, our data strengthen the
hypothesis that the presence of sugar substituents could partly
determine the afﬁnity binding of ML to various mammalian and
nematode Pgps.
4.2. Binding of other anthelmintics on Cel-Pgp-1
In silico docking calculations for other AH drugs belonging to
various chemical classes brought additional information about the
molecular mechanisms of multispeciﬁc recognition properties
exhibited by Cel-Pgp-1. The chemical diversity of the tested AHs
revealed the wide range of ligand-protein interactions accessible in
this putative multidrug transporter. In particular, a largemajority of
docking positions were found within the inner chamber, indicating
its pivotal role in the initial step of recognition and binding of
substrate drugs. The very negative binding energies of the four
hydrophobic AHs, TCZ, CLO, MNP and EMD, indicate that Cel-Pgp-1
might efﬁciently transport them, favoring the possible contribution
of this protein to AH drug resistance. However, two noticeable
exceptions were observed for TBZ and LEV, whose best binding
energy clusters included poses located at themembrane limit of the
transmembrane helix bundle. Such a binding position makes the
translocation of these two substrates unlikely. The hypothesis that
these drug binding sites are not relevant for active transmembrane
drug translocation is thus favored. We cannot, however, exclude
that these binding sites can play some functional, allosteric regu-
latory role, which would be desirable to test in vitro. In contrast, the
conformations of the second lowest energy clusters for TBZ and LEV
appeared to be localized within the inner chamber, but with less
favorable binding energy (5.7 and 6.1 kcal/mol, respectively). It
remains to be evaluated, in vitro, whether these “weak ligands”
actually interact with Cel-Pgp-1 at biochemically/pharmacologi-
cally relevant concentrations.
Remarkably, among the total 87 interacting residues encom-
passed by the docking positions of the 6 tested AHs found in the
inner chamber, 57 (i.e. 66%) are hotspot residues. Once again, this
high ratio provides an indication of a common structural template
for multispeciﬁc recognition shared by Cel-Pgp-1 and mammalian
Pgp, although their respective drug handling proﬁles do not fully
overlap, possibly due to differences in the balance of hydrophobic/
polar residues lining the inner chamber. Interestingly, TCZ, CLO and
EMD have been reported to interact with mammalian Pgp (Dupuy
et al., 2010; Elmshauser et al., 2014), whereas TBZ and LEV were
shown not to interact with mammalian Pgp (Dupuy et al., 2010;
Efferth and Volm, 1993; Hayeshi et al., 2006).
4.3. Usefulness and applicability of this structural model of
multispeciﬁc drug binding
Globally, this in silico analysis of ML binding on Cel-Pgp-1 pro-
vides a new, detailed vision of the ﬁne molecular mechanisms of
multispeciﬁc recognition capacities of a putative multidrug trans-
porter. Altogether, our data based on a large selection of potential
ligands are convergent to reveal that the inner chamber forms a
large multi-speciﬁc binding domain composed of somecontinuously connected sub-sites. This representation can help in
understanding or predicting mutual relationships of recognized
ligands, depending on the sub-site(s) they potentially bind and the
overlaps between sub-sites. In particular, the smallest size ligands,
such as TCZ andMNP, can be predicted to bindwith a stoichiometry
of 2, while some others, such as MOX, display “dual” binding site
with two different, partially overlapping positions. These different
conﬁgurations illustrate the palette of possible interactions offered
by all the contact residues lining this chamber, and the large size of
the multidrug binding domain. This is clearly at variance with the
standard depiction of ligand-receptor interaction typically given by
the “lock-and-key”mechanism. Overall, Cel-Pgp-1 and mammalian
Pgp appear to share common structural features in their respective
inner chambers based on the high proportion of hotspots residues
in Cel-Pgp-1, aligned (but often not identical) with residues
involved in multidrug recognition in mammalian Pgp.
More relevant pharmacologically is the observation of over-
lapping docking positions for ML and the AH drugs, TCZ, CLO, EMD
andMNP, which permits the prediction that simultaneous presence
of a ML and one of these compounds would lead to competitive
binding on, and hence transport by, Cel-Pgp-1. This needs of course
to be conﬁrmed experimentally, but if so, it could be inferred as
advantageous to administer a Cel-Pgp-1-mediated resistant worm
a combination of a ML with one of these compounds.
This model can be the basis for establishing similar drug binding
models on ABC transporters of parasitic nematodes showing suf-
ﬁcient sequence similarity with Cel-Pgp-1, in order to allow reliable
structure rebuilding by homology modelling. This strategy could be
powerful to test in silico the transporters capacities to exhibit either
selective or multiple AH drug binding. In the C. elegans genome, 14
Pgp-related ABC genes show differential expression levels during
the worm life cycle and various tissue localizations (Zhao et al.,
2004) (Wormbase: http://www.wormbase.org/). The closest ho-
mologs of Cel-Pgp-1, expressed in the intestine, are the ABC full
transporters of the sub-family B and its orthologs in other nema-
todes. For example, in H. contortus, if we restrict the computation of
sequence identity to TMD1-TMD2 regions, we observe that Hco-
Pgp-1 displays 63% sequence identity with Cel-Pgp-1, while the
latter shares only between 22% (Cel-Pgp-11) and 48% (Cel-Pgp-9) of
sequence identity with all other Cel-Pgp sequences of the same
genome. Thus, Hco-Pgp-1 would be the most direct candidate in
this parasite to beneﬁt from a similar in silico approach for AH drugs
docking on its structural model.
Therefore, based on the Cel-Pgp-1 structural model of multidrug
binding, describing the set of interacting residues lining the inner
chamber where ML bind speciﬁcally on a given nematode Pgp, will
be pivotal for the screening or rational design of optimized ligands
with high afﬁnity and selectivity. Such molecules would competi-
tively inhibit the transport of AH drugs in nematodes and could be
used to increase AH efﬁcacy. For this, it will be important to check
for the speciﬁcity of the designed inhibitor for nematode Pgps, to
avoid toxic effects in hosts. This is especially important in some
mammals, such as some collie dogs with defective Pgp transporters
in the blood-brain barrier which are highly sensitive to ivermectin,
due to excess of drug accumulation into the brain and subsequent
neurotoxicity (Roulet et al., 2003; Schinkel et al., 1994). Such data
would point to in vitro and in vivo experiments relevant for inves-
tigating the involvement of the ABC transporters in nematode drug
transport and resistance, and they could provide a clue for ﬁnding
speciﬁc efﬁcient AH resistance reversing agents.
In conclusion, in this in silico work based on a recently released
crystal structure of the nematode C. elegans ABC transporter Pgp-1,
we showed for the ﬁrst time that most of the AH drugs currently
used in veterinary and human medicine to treat helminth in-
fections can be substrates of Cel-Pgp-1. We clearly identiﬁed
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different ML interacting with speciﬁc sub-sites of the binding
pocket of Cel-Pgp-1, which can be targeted to designmolecules that
would inhibit ML binding to this transporter in the perspective of
necessary high host/nematode selectivity. Such information on the
key residues, in mammalian Pgp and in nematode Pgp, which
interact with the different compounds, should also provide insights
for the design of novel anthelmintic analogs which are non-ligands,
thus unlikely to be subject to efﬂux-based mechanisms of drug
resistance development in nematodes. The model that we have
developed could hence generally be used to assess the possible
interactions of new chemical entities with nematode Pgp. This
model is a critical insight into the possible role of Pgp homologs in
expelling AH drugs out of parasite nematodes, making them
resistant to treatment. Furthermore, this is the necessary step to
identify in combination with in silico-guided in vitro experiments,
the ABC transporters (at least from the B sub-family) speciﬁcally
responsible for AH resistance, in order to rationally design or select
speciﬁc inhibitors that could be novel therapeutic weapons against
AH resistant parasites.
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